Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose chemotherapy of solid tumours

J Crown1

  • 1St. Vincent's Hospital, Dublin, Ireland.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 1, 1995
PubMed
Summary

High-dose chemotherapy (HDC) with stem cell support shows high response rates in solid tumors like breast cancer, but its survival benefits require further study. Randomized trials are needed to confirm efficacy and quantify advantages.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025
Same author

Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

British journal of cancer·2025
Same author

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.

Breast cancer research and treatment·2021
Same author

Differentiation of intracranial meningioma from dural metastasis with somatostatin receptor scintigraphy: An underutilised solution to a common problem.

QJM : monthly journal of the Association of Physicians·2020

Area of Science:

  • Oncology
  • Hematology

Background:

  • High-dose chemotherapy (HDC) with autologous haematopoietic stem cell support is utilized for various solid tumors.
  • Its efficacy is well-studied in breast cancer, serving as a model for other solid malignancies.

Purpose of the Study:

  • To discuss the role and controversy surrounding HDC in solid tumors.
  • To evaluate the potential survival advantages of HDC compared to standard treatments.
  • To propose further research directions for HDC optimization.

Main Methods:

  • Review and discussion of existing data on HDC in solid tumors, particularly breast cancer.
  • Comparative analysis with other solid tumors like ovarian, testicular, and small-cell lung cancer.
  • Proposal for randomized controlled trials to assess survival benefits.

Main Results:

  • HDC demonstrates high response rates in patients with solid tumors.
  • Breast cancer serves as a primary model for HDC research.
  • The overall survival advantage of HDC remains to be definitively quantified.

Conclusions:

  • HDC offers significant response rates but its controversial status necessitates further investigation.
  • Randomized trials are crucial for establishing and quantifying survival benefits.
  • Continued research and development are indicated for optimizing HDC strategies.

Related Experiment Videos